Immatics (NASDAQ:IMTX – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday, Zacks.com reports. According to Zacks, “Immatics N.V. engages in the discovery of targets for cancer immunotherapies. It is developing targeted immunotherapies with focus on treating solid tumors. […]
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Rating) CEO John F. Crowley sold 2,214 shares of the business’s stock in a transaction on Monday, April 18th. The shares were sold at an average price of $8.04, for a total transaction of $17,800.56. Following the sale, the chief executive officer now owns 974,221 shares of the company’s […]
Zacks Investment Research upgraded shares of Immatics (NASDAQ:IMTX – Get Rating) from a hold rating to a buy rating in a research report sent to investors on Thursday morning, Zacks.com reports. The firm currently has $10.00 price objective on the stock. According to Zacks, “Immatics N.V. engages in the discovery of targets for cancer immunotherapies. […]
Wall Street brokerages expect Immatics (NASDAQ:IMTX – Get Rating) to announce $1.86 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Immatics’ earnings. Immatics reported earnings per share of ($0.41) during the same quarter last year, which suggests a positive year over year growth rate of […]
Immatics (NASDAQ:IMTX – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday, Zacks.com reports. The firm currently has a $9.25 price target on the stock. Zacks Investment Research‘s price target would indicate a potential upside of 15.77% from the […]